Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Exopolysaccharide of Levilactobacillus brevis M-10 Improved Physiological and Biochemical Indicators and Gut Microbiota in DSS-Induced Colitis Mice
Publication Year: 2025 Source: Curr Microbiol PMID: 40126646
Ulcerative colitis (UC) is a typical type of inflammatory bowel disease, which is often recurrent and directly related with colorectal cancer. Therefore, early prevention and treatment for UC is very necessary. Therefore, it is necessary to find efficient substances to treat the UC with less side effects than drugs. Exopolysaccharides …
Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child
Publication Year: 2025 Source: J Crohns Colitis PMID: 40127036
BACKGROUND AND AIMS: Janus kinase (JAK) inhibitors, such as tofacitinib, are potent anti-inflammatory agents used in the treatment of ulcerative colitis (UC). Current guidelines recommend avoiding their use during pregnancy due to safety concerns, as well as during breastfeeding due to the potential excretion into breast milk. METHODS: This case …
The use of International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) in patients with ulcerative colitis: applicability and comparison with other ultrasound scores
Publication Year: 2025 Source: J Crohns Colitis PMID: 40127042
BACKGROUND AND AIMS: The International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) is an intestinal ultrasound (IUS) score validated for Crohn's disease, potentially applicable to ulcerative colitis (UC). We aimed to confirm the applicability of IBUS-SAS to UC, while comparing its performance with other IUS scores. METHODS: Adult patients with UC …
Angelicone Ameliorates Ulcerative Colitis in Mice via Modulating Gut Microbiota
Publication Year: 2025 Source: Planta Med PMID: 40127682
Ulcerative colitis (UC) is a persistent, periodically reoccurring inflammatory condition that impacts the gastrointestinal tract. Angelicone, a principal compound extracted from Angelica sinensis, may offer a potential alternative therapeutic approach for UC through the downregulation of inflammatory mediators. Nonetheless, the pharmacological impacts and molecular pathways of angelicone in UC management, …
Machine learning prediction of premature death from multimorbidity among people with inflammatory bowel disease: a population-based retrospective cohort study
Publication Year: 2025 Source: CMAJ PMID: 40127916 DOI: 10.1503/cmaj.241117
BACKGROUND: Multimorbidity, the co-occurrence of 2 or more chronic conditions, is important in patients with inflammatory bowel disease (IBD) given its association with complex care plans, poor health outcomes, and excess mortality. Our objectives were to describe premature death (age < 75 yr) among people with IBD and to identify …
Comprehensive flow cytometry-based diagnosis of XIAP deficiency
Publication Year: 2025 Source: Clin Exp Immunol PMID: 40128104
Deficiency of X-linked inhibitor of apoptosis protein (XIAP) is an X-linked recessive inborn error of immunity characterized by abnormal immune responses leading to inflammatory bowel disease and hemophagocytic lymphohistiocytosis. Although XIAP protein expression analysis by flow cytometry (XIAP flow) is commonly used to diagnose XIAP deficiency, certain variants may not …
Publisher Correction: Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities
Publication Year: 2025 Source: Nat Rev Microbiol PMID: 40128602
No Abstract
Reduction of colitis in mice by chemically programmed supramolecular nanoassemblies of vitamin-lipid conjugates
Publication Year: 2025 Source: J Nanobiotechnology PMID: 40128782 DOI: 10.1186/s12951-025-03322-0
Inflammatory bowel disease (IBD) is a relapsing disorder characterized by uncontrolled chronic inflammation of the gastrointestinal tract, posing a significant therapeutic challenge owing to the limited efficacy and undesirable side effects of current therapeutic options. A key pathological hallmark of IBD is the excessive production of reactive oxygen species (ROS). …
Coexistence of Relapsing Polychondritis, Crohn's Disease, and Pyoderma Gangrenosum Treated Successfully with Adalimumab: A Case Report and Literature Review
Publication Year: 2025 Source: Intern Med PMID: 40128993
Relapsing polychondritis (RP) is a rare, progressive, immune-mediated systemic inflammatory disease of unknown etiology characterized by recurrent inflammation of cartilaginous structures. Approximately 30% of RP cases are associated with autoimmune disease. However, co-occurrence of RP and Crohn's disease (CD) has rarely been reported. We herein report a case of coexisting …
The significance of individual patient characteristics in a cohort of patients with inflammatory bowel disease treated with vedolizumab
Publication Year: 2025 Source: Med Glas (Zenica) PMID: 40129319 DOI: 10.17392/1770-22-01
AIM: Care for the inflammatory bowel disease (IBD) patients presents unique challenges as decisions regarding therapy must consider numerous distinct characteristics of each patient. The aim of the study was to recognize patients' characteristics as predictors of success in vedolizumab treatment. METHODS: In a retrospective observational study, data regarding age, …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide